Achilles Therapeutics Plc has appointed the biopharmaceutical veteran Bernhard Ehmer to its board of directors as it advances its T cell therapies for cancer in the clinic. Dr Ehmer most recently served as chief executive of Biotest AG, a specialist supplier of plasma proteins and biotherapeutic drugs. He has also served as chairman of the board of directors of Symphogen A/S of Denmark until its acquisition by Servier SA in 2020.
Achilles announced the appointment on 4 May 2022.
Copyright 2022 Evernow Publishing Ltd